Source: Breathe, 17 (4) 210114; 10.1183/20734735.0114-2021



Rating:

Share or cite this content

Citations should be made in the following way:
Zhe Wu, Philip L. Molyneaux. Choosing pharmacotherapy for ILD in patients with connective tissue disease. Breathe, 17 (4) 210114; 10.1183/20734735.0114-2021

Member's Comments

No comment yet.

Related content which might interest you: Pattern and impact of rheumatology referral in patients with ILD and autoimmune features Source: International Congress 2016 – Connective tissue disorders Year: 2016 Predictors of mortality and risk prediction among patients with scleroderma related interstitial lung disease Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 What if my lung-dominant connective tissue disease (LD-CTD) patient eventually met criteria for a definite CTD: The role of prognosis! Source: International Congress 2015 – Connective tissue disorders Year: 2015 Novel markers of connective tissue disease in patients with idiopathic interstitial pneumonia Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Interstitial lung disease in patients with connective tissue diseases - a report of 3 cases Source: Eur Respir J 2004; 24: Suppl. 48, 668s Year: 2004 Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD Source: International Congress 2016 – Connective tissue disorders Year: 2016 Evaluation and treatment of interstitial lung involvement in connective tissue diseases: a clinical update Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-39-1, page=27 Year: 2005 Co-morbidities and cause of death in patients with rheumatoid arthritis associated interstitial lung disease Source: International Congress 2015 – Connective tissue disorders Year: 2015 Characteristics and predictors of outcome in rheumatoid arthritis related ILD Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Relevance of the expert ILD clinical-radiological evaluation of referred cases to the MDT Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Interstitial lung disease Source: Eur Respir Rev 2013; 22: 26-32 Year: 2013 Serum KL-6 as a biomarker to assess response to azathioprine in connective tissue disease associated lung disease (CTD-ILD) Source: International Congress 2015 – Connective tissue disorders Year: 2015 Rituximab in severe, treatment-refractory interstitial lung disease Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Are there any clinical differences between SSc-ILD and UCTD suspected of SSc -ILD? Source: International Congress 2015 – Connective tissue disorders Year: 2015 An observational study on effectiveness of azathioprine in treatment of interstitial lung disease secondary to connective tissue disease Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 Features of pulmonary involvement in patients with diffuse connective tissue diseases Source: Annual Congress 2011 - Rare diffuse lung diseases Year: 2011 Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy}, Source: Eur Respir J 2012; 40: 641-648 Year: 2012 A multicentre evaluation of inter-multidisciplinary team agreement for predicted disease behaviour and management strategy in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016